In silico screening: identification of a novel CDK-1 inhibitor from Chrysophyllum cainito leaves

Abstract

Increasing evidence suggests that OSCC overexpresses CDK-1 to promote its advancement, which intervene in the paclitaxel effects. As a result of drug resistance and immune evasion, treating the advanced stage of OSCC has proven challenging. Therefore, a CDK-1 inhibitor with high inhibitory activity, excellent pharmacokinetic activities, and minimal adverse effects is urgently needed. Our study has uncovered novel CDK-1 inhibitors, which would be beneficial and expected to reinstate the paclitaxel-resistant while treating combined with our novel inhibitors in the future.